Graphic designer Thesis Last March, I made my debut in Seeking Alpha by analyzing Takeda Pharmaceutical Company Limited (NYSE:TAK). In the article, I highlighted that the company was showing signs of improvement, despite the decline of revenue from key areas such as oncology and neurosciences. Among those signs were the revenue increase observed from the gastrointestinal and inflammation sector, the approval of Eohilia, the announcement of Milano Furuta as new Chief Financial Officer (CFO), who took the rol ...

115 The following table shows the number of shares as of March 31, 2024 owned by directors of the Company as of the date of this annual report. Table of Contents F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation Not applicable. A. Major Shareholders B. Related Party Transactions C. Interests of Experts and Counsel Our audited consolidated financial statements are included under "Item 18—Financial Statements." Takeda's policy in the allocation of capital is as follows: • Inve ...

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) Form 20-F ☒ Form 40-F ☐ Exhibit Number Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-38757 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or ...

1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Celiac Disease - Introduction 4.1 Overview 4.2 Regulatory Process This report also provides a detailed analysis of the current celiac disease marketed drugs and late-stage pipeline drugs. Drug Overview Mechanism of Action Regulatory Status Clinical ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Fiscal Year 2023 Earnings Conference Call May 9, 2024 6:00 AM ET Company Participants Christopher O’Reilly – Head-Investor Relations Christophe Weber – President and Chief Executive Officer Andy Plump – President of R&D Milano Furuta – Chief Financial Officer Ramona Sequeira – President of Global Portfolio Division Julie Kim – President of U.S. Business Unit Giles Platford – President, PDT Business Unit Conference Call Participants Steve Barker – Jefferies Hi ...

The most closely comparable measure presented in accordance with IFRS is net profit for the period. Please refer to Net Profit to Adjusted EBITDA Bridge for a reconciliation to the respective most closely comparable measures presented in accordance with IFRS. The most directly comparable measures under IFRS for Net Debt is bonds and loans. Please refer to Net Debt to Adjusted EBITDA for a reconciliation to this measure. A-3 When comparing results to the same period of the previous fiscal year, the amount of ...

Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2024 ________________________________________ TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) ________________________________________ 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, To ...

On oncology, if we can bring new assets like [Indiscernible] fruquintinib that we just in-licensed, that would be terrific. So we are looking at this type of deals to complement our portfolio. We have a very attractive pipeline, but it's more mid-stage. So many of these products in our pipeline will be launched towards the end of the decade. So if we can bring more assets to enrich our portfolio, we'll do. Unidentified Company Representative Company Participants Conference Call Participants Christopher O'Re ...

 Our results at constant exchange rate are tracking well against our full year management guidance for fiscal year 2023 and there is no change to our guidance at this time. Looking ahead, we are continuing to work closely with the WHO and look forward to the release of the recommendation from SAGE, the WHO advisory group, which is anticipated later this year. I should also note the important notices are attached to the presentation material. We are proud of all this progress, which represents the potential ...

As filed with the Securities and Exchange Commission on June 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ___________________________________________________________ ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANS ...